STOCK TITAN

Cybin Inc Stock Price, News & Analysis

CYBN NYSE

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.

Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.

Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.

Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.

Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) has announced a conference call and webcast scheduled for November 18, 2024, at 8:00 a.m. ET. The presentation will feature 12-month efficacy and safety data from the company's Phase 2 study of CYB003 in Major Depressive Disorder, along with details about the recently initiated Phase 3 PARADIGM program. The event will be led by CEO Doug Drysdale and CMO Amir Inamdar, followed by a Q&A session for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
conferences clinical trial
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) has initiated PARADIGM, a Phase 3 pivotal program evaluating CYB003 for Major Depressive Disorder (MDD) treatment. The program includes two 12-week randomized studies: APPROACH (220 patients across U.S. and Europe) and EMBRACE (starting 1H25), plus a long-term extension study EXTEND. The company reports C$154.3 million cash as of September 30, 2024. CYB003 targets a market of >300 million people worldwide and 21 million in the U.S. Topline results are expected in 2026, with 12-month Phase 2 efficacy data expected in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) announced its participation in the 2024 Milken Institute Future of Health Summit. CEO Doug Drysdale will speak on a panel titled 'The Next Frontier in Mental Health Research' on November 13, 2024, in Washington DC.

The discussion will focus on novel approaches to mental health treatments. Drysdale will share updates on Cybin's clinical advancements, including CYB003, their deuterated psilocin program for major depressive disorder entering Phase 3, and CYB004, their deuterated DMT program in Phase 2 for generalized anxiety disorder.

The panel will address mental illness, which affects one in eight people globally, exploring new therapeutic approaches and personalized treatment solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
conferences
Rhea-AI Summary

Cybin has been granted U.S. patent 12,122,741 by the USPTO for composition of matter claims related to its CYB005 phenethylamines program. The company is investigating these novel molecules at non-hallucinogenic doses for various Central Nervous System disorders. The development includes exploring non-hallucinogenic neuroplastogens and targeted serotonin 5-HT1A and 5-HT2C receptor agonists. This addition brings Cybin's intellectual property portfolio to over 70 granted patents and more than 220 pending patent applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has announced its participation in the Water Tower Research Fireside Chat Series on October 8, 2024, at 3:00 p.m. ET. The event will feature Doug Drysdale, Cybin's CEO, in a discussion hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research.

The fireside chat will cover key topics including:

  • Cybin's lead development programs CYB003 and CYB004 and upcoming clinical milestones
  • Differentiators in Cybin's development approach compared to other neuropsychiatric developments
  • Lessons learned and applied from the FDA's Lykos NDA rejection

Interested parties can register for the webcast through a provided link. An archived version of the webcast will be available on Cybin's investor relations website after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) has expanded its clinical team to support the upcoming Phase 3 pivotal program for CYB003 in Major Depressive Disorder (MDD). Key appointments include:

- Dr. Mirza Rahman as Senior VP, Patient Safety & Pharmacovigilance
- Dr. Marcelo Gutierrez as VP, Clinical Pharmacology
- Dr. Atul R. Mahableshwarkar as program lead for CYB003
- Dr. Tom Macek as program lead for CYB004

The strengthened team will support CYB003 pivotal trials, consisting of three studies spanning up to 12 countries. These additions bring expertise in patient safety, pharmacovigilance, clinical pharmacology, and drug development, important for advancing Cybin's proprietary deuterated psilocin program for adjunctive treatment of MDD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event will take place on September 26, 2024.

Amir Inamdar, Cybin's Chief Medical Officer, will be part of a panel discussion titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'. The panel will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET.

Interested parties can access the webcast through a provided link. An archived version of the webcast will also be available on Cybin's investor relations website under the Events & Presentations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
conferences
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, provided updates on its key clinical programs. The company is preparing to initiate a pivotal Phase 3 study for CYB003, its deuterated psilocin program for Major Depressive Disorder (MDD), which has received FDA Breakthrough Therapy Designation. Cybin expects to report 12-month efficacy data from the Phase 2 study of CYB003 in early Q4 2024.

For CYB004, Cybin's deuterated dimethyltryptamine program for Generalized Anxiety Disorder (GAD), the company anticipates Phase 2 topline efficacy and safety results by year-end 2024 or early Q1 2025. Cybin has also strengthened its R&D team with the addition of Dr. Atul R. Mahableshwarkar and Dr. Tom Macek as program leads for CYB003 and CYB004, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
none
-
Rhea-AI Summary

Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has completed a share consolidation on a 38:1 basis. The consolidation, effective immediately, reduces the company's outstanding common shares from 759,692,495 to approximately 19,991,907. Trading of the consolidated shares begins today. This move does not affect shareholders' ownership percentages or voting power, except for minor adjustments due to fractional shares. The company has also adjusted the exercise price and number of shares issuable for outstanding warrants and options in line with the consolidation ratio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4096.08%
Tags
none
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York, NY. CEO Doug Drysdale will engage in a fireside chat on Monday, September 9, 2024, at 8:30 a.m. ET, which will be webcast live and later archived on the company's investor relations website.

Additionally, Drysdale will join a panel discussion titled "Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders" on Tuesday, September 10, 2024, at 3:00 p.m. ET. This event highlights Cybin's commitment to developing innovative next-generation treatment options for mental healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $6.08 as of May 6, 2025.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 144.5M.
Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Stock Data

144.45M
18.64M
238.24%
41.95%
5.19%
Biotechnology
Healthcare
Link
Canada
Toronto